(Sharecast News) - Shares in Eli Lilly jumped on Wall Street on Tuesday after the American pharma giant beat quarterly profit forecasts and hiked its full-year sales guidance by $2bn, helped by surging demand for its weight-loss drug Zepbound.
The company is now guiding to full-year revenues of $42.4bn-$43.6bn, from $40.4bn-$41.6bn...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE